Authors: SCHWARTZ JI TANAKA WK WANG DZ EBEL DL GEISSLER LA DALLOB A HAFKIN B GERTZ BJ

Citation: Ji. Schwartz et al., MK-386, AN INHIBITOR OF 5-ALPHA-REDUCTASE TYPE-1, REDUCES DIHYDROTESTOSTERONE CONCENTRATIONS IN SERUM AND SEBUM WITHOUT AFFECTING DIHYDROTESTOSTERONE CONCENTRATIONS IN SEMEN, The Journal of clinical endocrinology and metabolism, 82(5), 1997, pp. 1373-1377

Authors: EHRICH E DALLOB A VANHECKEN A DEPRE M DELEPELEIRE I BRIDEAU C HILLIARD D TANAKA W MUKHOPADHYAY S SEIBOLD J DESCHEPPER P GERTZ B

Citation: E. Ehrich et al., DEMONSTRATION OF SELECTIVE COX-2 INHIBITION BY MK-966 IN HUMANS, Arthritis and rheumatism, 39(9), 1996, pp. 328-328

Authors: WALDSTREICHER J FIEDLER V HORDINSKY M SWINEHART JM THIBOUTOT D UNGER W LOWE NJ JACOBSON C STIEGLITZ S KRAUS SJ WEISS D CARRINGTON PR GENCHEFF CA COLE G DRAKE L PARISER DM EPSTEIN ES TANAKA WK DALLOB A MOORE E NGUYEN HH BINKOWITZ B KAUFMAN DK GORMLEY GJ

Citation: J. Waldstreicher et al., EFFECTS OF FINASTERIDE ON DIHYDROTESTOSTERONE CONTENT OF SCALP SKIN IN MEN WITH MALE PATTERN BALDNESS, Journal of investigative dermatology, 102(4), 1994, pp. 615-615

Authors: DEPRE M FRIEDMAN B VANHECKEN A DELEPELEIRE I TANAKA W DALLOB A SHINGO S PORRAS A LIN C DESCHEPPER PJ

Citation: M. Depre et al., PHARMACOKINETICS AND PHARMACODYNAMICS OF MULTIPLE ORAL DOSES OF MK-0591, A 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITOR, Clinical pharmacology and therapeutics, 56(1), 1994, pp. 22-30